Compounds > cilomilast
Page last updated: 2024-09-04

cilomilast and sildenafil

cilomilast has been researched along with sildenafil in 7 studies

Compound Research Comparison

Studies
(cilomilast)		Trials
(cilomilast)		Recent Studies (post-2010)
(cilomilast)		Studies
(sildenafil)		Trials
(sildenafil)		Recent Studies (post-2010) (sildenafil)
1621342134060

Protein Interaction Comparison

ProteinTaxonomycilomilast (IC50)sildenafil (IC50)
Chain A, cAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)20
Chain A, cAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)20
Chain A, cAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)20
Chain A, cAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)20
Chain A, cAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)20
Chain A, cAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)20
Chain A, cAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)20
Chain A, cAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)20
Chain A, cAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)20
Chain A, cAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)20
Chain A, cAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)20
Chain B, cAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)20
Chain A, cGMP-specific 3',5'-cyclic phosphodiesteraseHomo sapiens (human)20
Chain A, cGMP-specific 3',5'-cyclic phosphodiesteraseHomo sapiens (human)20
Chain A, cGMP-specific 3',5'-cyclic phosphodiesteraseHomo sapiens (human)0.0024
Chain A, cGMP-specific 3',5'-cyclic phosphodiesteraseHomo sapiens (human)0.0024
Phosphodiesterase Bos taurus (cattle)9.2
cGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)2.881
Retinal rod rhodopsin-sensitive cGMP 3',5'-cyclic phosphodiesterase subunit deltaHomo sapiens (human)0.0187
cGMP-specific 3',5'-cyclic phosphodiesteraseRattus norvegicus (Norway rat)0.0012
High affinity cAMP-specific and IBMX-insensitive 3',5'-cyclic phosphodiesterase 8AHomo sapiens (human)2.881
cGMP-specific 3',5'-cyclic phosphodiesteraseHomo sapiens (human)0.2626
High affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9AHomo sapiens (human)4.2
cGMP-specific 3',5'-cyclic phosphodiesteraseCanis lupus familiaris (dog)0.0024
Retinal rod rhodopsin-sensitive cGMP 3',5'-cyclic phosphodiesterase subunit gammaBos taurus (cattle)0.0374
Replicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus8.247
Replicase polyprotein 1abSevere acute respiratory syndrome coronavirus 28.247
Rod cGMP-specific 3',5'-cyclic phosphodiesterase subunit alphaBos taurus (cattle)0.0545
Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1A Bos taurus (cattle)0.78
cAMP-specific 3',5'-cyclic phosphodiesterase 4D Rattus norvegicus (Norway rat)4.6
cAMP-specific 3',5'-cyclic phosphodiesterase 4CRattus norvegicus (Norway rat)4.6
cAMP-specific 3',5'-cyclic phosphodiesterase 4BRattus norvegicus (Norway rat)4.6
Rod cGMP-specific 3',5'-cyclic phosphodiesterase subunit alphaHomo sapiens (human)0.0187
Cone cGMP-specific 3',5'-cyclic phosphodiesterase subunit alpha'Bos taurus (cattle)0.0366
Retinal rod rhodopsin-sensitive cGMP 3',5'-cyclic phosphodiesterase subunit gammaHomo sapiens (human)0.0187
Retinal cone rhodopsin-sensitive cGMP 3',5'-cyclic phosphodiesterase subunit gammaBos taurus (cattle)0.0374
Rod cGMP-specific 3',5'-cyclic phosphodiesterase subunit betaBos taurus (cattle)0.0374
cAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)7.9333
Adenosine receptor A2aHomo sapiens (human)0.253
Adenosine receptor A1Homo sapiens (human)1.493
Delta-type opioid receptorRattus norvegicus (Norway rat)0.04
Prostaglandin G/H synthase 2Homo sapiens (human)0.003
Rod cGMP-specific 3',5'-cyclic phosphodiesterase subunit betaHomo sapiens (human)0.0187
Cone cGMP-specific 3',5'-cyclic phosphodiesterase subunit alpha'Homo sapiens (human)0.0418
cAMP-specific 3',5'-cyclic phosphodiesterase 4ARattus norvegicus (Norway rat)4.6
Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1AHomo sapiens (human)0.7199
Retinal rod rhodopsin-sensitive cGMP 3',5'-cyclic phosphodiesterase subunit gammaCanis lupus familiaris (dog)0.0182
Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1BBos taurus (cattle)0.78
Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1BHomo sapiens (human)1.8841
Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1BRattus norvegicus (Norway rat)0.3
Synaptic vesicular amine transporterRattus norvegicus (Norway rat)0.01
cAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)6.3336
cAMP-specific 3',5'-cyclic phosphodiesterase 4CHomo sapiens (human)8.52
cAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)5.7005
Potassium voltage-gated channel subfamily H member 2Homo sapiens (human)3.3075
cGMP-inhibited 3',5'-cyclic phosphodiesterase BHomo sapiens (human)4.7337
High affinity cAMP-specific 3',5'-cyclic phosphodiesterase 7AHomo sapiens (human)4.69
Retinal cone rhodopsin-sensitive cGMP 3',5'-cyclic phosphodiesterase subunit gammaHomo sapiens (human)0.0187
Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1CHomo sapiens (human)0.7398
cGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)4.6677
cGMP-specific 3',5'-cyclic phosphodiesteraseBos taurus (cattle)0.557
Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1CRattus norvegicus (Norway rat)0.3
Indoleamine 2,3-dioxygenase 2Mus musculus (house mouse)4.5
Retinal rod rhodopsin-sensitive cGMP 3',5'-cyclic phosphodiesterase subunit deltaBos taurus (cattle)0.0374
Phosphodiesterase Rattus norvegicus (Norway rat)0.3
Dual 3',5'-cyclic-AMP and -GMP phosphodiesterase 11AHomo sapiens (human)4.1584
cAMP-specific 3',5'-cyclic phosphodiesterase 7BHomo sapiens (human)3.6006
cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10AHomo sapiens (human)4.2432

Research

Studies (7)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's4 (57.14)29.6817
2010's3 (42.86)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Artis, DR; Bollag, G; Card, GL; England, BP; Fong, D; Gillette, S; Ibrahim, PN; Kim, SH; Lee, B; Luu, C; Milburn, MV; Powell, B; Schlessinger, J; Suzuki, Y; Tabrizizad, M; Zhang, KY1
Hughes, RA; Manallack, DT; Thompson, PE1
Lombardo, F; Obach, RS; Waters, NJ1
Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV1
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV1
Barlow, DJ; Ehrman, TM; Hylands, PJ1
de Esch, IJ; de Graaf, C; Jansen, C; Kanev, GK; Kooistra, AJ; Leurs, R1

Reviews

1 review(s) available for cilomilast and sildenafil

ArticleYear
The next generation of phosphodiesterase inhibitors: structural clues to ligand and substrate selectivity of phosphodiesterases.
    Journal of medicinal chemistry, 2005, May-19, Volume: 48, Issue:10

    Topics: Animals; Binding Sites; Crystallography, X-Ray; Cyclic AMP; Cyclic GMP; Drug Design; Humans; Models, Molecular; Molecular Structure; Phosphodiesterase Inhibitors; Quantitative Structure-Activity Relationship; Xanthines

2005

Other Studies

6 other study(ies) available for cilomilast and sildenafil

ArticleYear
Structural basis for the activity of drugs that inhibit phosphodiesterases.
    Structure (London, England : 1993), 2004, Volume: 12, Issue:12

    Topics: Binding Sites; Crystallography, X-Ray; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Protein Structure, Tertiary

2004
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
    Drug metabolism and disposition: the biological fate of chemicals, 2008, Volume: 36, Issue:7

    Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding

2008
Physicochemical determinants of human renal clearance.
    Journal of medicinal chemistry, 2009, Aug-13, Volume: 52, Issue:15

    Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight

2009
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
    Journal of medicinal chemistry, 2010, Feb-11, Volume: 53, Issue:3

    Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations

2010
In silico search for multi-target anti-inflammatories in Chinese herbs and formulas.
    Bioorganic & medicinal chemistry, 2010, Mar-15, Volume: 18, Issue:6

    Topics: Anti-Inflammatory Agents; Crystallography, X-Ray; Cyclooxygenase 1; Cyclooxygenase 2; Databases, Factual; Drug Design; Drugs, Chinese Herbal; Enzyme Inhibitors; JNK Mitogen-Activated Protein Kinases; Medicine, Chinese Traditional; Models, Chemical; Models, Molecular; Molecular Conformation; p38 Mitogen-Activated Protein Kinases; Phosphodiesterase 4 Inhibitors; Structure-Activity Relationship

2010
PDEStrIAn: A Phosphodiesterase Structure and Ligand Interaction Annotated Database As a Tool for Structure-Based Drug Design.
    Journal of medicinal chemistry, 2016, Aug-11, Volume: 59, Issue:15

    Topics: Databases, Protein; Dose-Response Relationship, Drug; Drug Design; Humans; Ligands; Models, Molecular; Molecular Structure; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Structure-Activity Relationship

2016